- cafead   May 25, 2021 at 11:42: AM
via Exelixis has blockbuster dreams for its Cabometyx drug, and it’s looking to capitalize in the prostate cancer market by combining it with Roche’s Tecentriq. But after a new data readout Monday drew concerns from analysts, its future in the area appears more cloudy.
article source
article source